News

Article

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

Author(s):

The European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refractory follicular lymphoma or relapsed/refractory diffuse large B-cell lymphoma who have progressed after at least 2 prior systemic therapies.

The European Medicines Agency (EMA) has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refractory (R/R) follicular lymphoma or R/R diffuse large B-cell lymphoma (DLBCL) who have progressed after at least 2 prior systemic therapies.1

The application is supported by data from the phase 1 ELM-1 trial (NCT02290951) and the pivotal phase 2 ELM-2 trial (NCT03888105).

Data presented at the 2022 ASH Annual Meeting showed that patients with relapsed/refractory DLBCL enrolled in a phase 2 cohort who were naïve to CAR T-cell therapy (n = 130) experienced an objective response rate (ORR) of 49% and a complete response (CR) rate of 31% at a median follow-up of 21 months (range, 3-30). The median duration of CR was 18 months (95% CI, 10-not evaluable [NE]).2

In patients who were exposed to prior CAR T-cell therapy treated in a phase 1 dose-expansion cohort (n = 31), the ORR was 48% with a CR rate of 32%. The median duration of CR was not reached (NR; 95% CI, 2-NE).

Regarding safety, any-grade adverse events (AEs) were reported in 99% of evaluable patients in the phase 2 cohort (n = 140), and 79% experienced grade 3 or higher AEs. The most common any-grade AEs reported in at least 20% of patients included cytokine release syndrome (CRS; 55%), anemia (42%), pyrexia (39%), neutropenia (28%) and hypokalemia (20%).

Ten percent of patients discontinued treatment due to AEs. AEs led to 5 deaths, owing to pneumonia (n = 3), COVID-19 (n = 1) and pseudomonal sepsis (n = 1), and the relationship of odronextamab to these AEs could not be excluded.

Regarding CRS, 64% of events were grade 1, and all instances of CRS resolved. The median time to CRS resolution was 2 days (range, 1-133). No grade 4 or 5 CRS was reported, and instances of grade 2 or higher CRS were reduced with the modified step-up regimen compared with the original regimen. Among 67 patients treated with the original regimen, the rates of grade 2 and 3 CRS were 18% and 7.5%, respectively. Among the 73 patients treated with the step-up regimen, those rates were 14% and 1%, respectively.

In a relapsed/refractory follicular lymphoma cohort from ELM-2 (n = 121), patients achieved an ORR of 82% with a CR rate of 75% at a median follow-up of 22 months (range, 3-33).3 The median duration of CR was 20.5 months (95% CI, 17-NE). The median progression-free survival (PFS) and overall survival (OS) were 20 months (95% CI, 15-NE) and NR (95% CI, NE-NE), respectively.

Safety findings from this cohort showed that all patients (n = 131) experienced any-grade AEs, and grade 3 or higher AEs occurred in 78% of patients. The most common AEs reported in at least 20% of patients included CRS (56.5%), neutropenia (40%), pyrexia (31%), anemia (30%), infusion-related reaction (29%), arthralgia (21%), diarrhea (21%) and thrombocytopenia (20%). Additionally, AEs led to treatment discontinuation in 11.5% of patients. Three deaths were reported due to pneumonia, progressive multifocal leukoencephalopathy, and systemic mycosis, and odronextamab was possibly related to these events.

Sixty-eight percent of CRS events were grade 1, and all resolved at a median duration of 2 days (range, 1-51). No grade 4 or 5 CRS was reported. Patients treated with the step-up regimen (n = 63) experienced rates of grade 2 and 3 CRS of 11% and 2%, respectively. The rates of grade 2 and 3 CRS in patients treated with the original regimen (n = 68) were 18% and 6%, respectively.

ELM-2 is an ongoing, open-label, multicenter, phase 2 trial investigating odronextamab in more than 500 patients in 5 independent, disease-specific cohorts, including DLBCL, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and other subtypes of B-cell non-Hodgkin lymphoma. Patients in the follicular lymphoma cohort are required to have central histopathologic confirmation of the grade 1 to 3A disease. In other disease-specific cohorts, patients need to have disease that has relapsed after or is refractory to at least 2 prior lines of systemic therapy.4

The primary end point is ORR per Lugano Classification. Secondary end points include CR rate, investigator-assessed ORR, PFS, OS, duration of response (DOR), disease-control rate, safety, and quality of life.1

The open-label, multicenter, phase 1 ELM-1 trial examined the safety and tolerability of odronextamab in patients with CD20-positive B-cell malignancies previously treated with CD20-directed antibody therapy. Patients with grade 1 to 3A follicular lymphoma and DLBCL were required to have received at least 2 prior lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent.5

The primary end points were safety, dose-limiting toxicities, and ORR. Secondary end points consisted of pharmacokinetics, anti-drug antibodies, PFS, OS, DOR, and duration of CR.

References

  1. Odronextamab receives EMA filing acceptance for treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. News release. Regeneron Pharmaceuticals. August 17, 2023. Accessed August 17, 2023. https://investor.regeneron.com/news-releases/news-release-details/odronextamab-receives-ema-filing-acceptance-treatment
  2. Pivotal odronextamab (CD20xCD3) phase 2 data in patients with relapsed/refractory diffuse large B-cell lymphoma debut at ASH. News release. Regeneron Pharmaceuticals. December 11, 2022. Accessed August 17, 2023. https://investor.regeneron.com/news-releases/news-release-details/pivotal-odronextamab-cd20xcd3-phase-2-data-patients
  3. Odronextamab (CD20xCED3) demonstrates high and durable complete response rate among patients with relapsed/refractory follicular lymphoma in pivotal phase 2 trial. News release. Regeneron Pharmaceuticals. December 12, 2022. Accessed August 17, 2023. https://investor.regeneron.com/news-releases/news-release-details/odronextamab-cd20xcd3-demonstrates-high-and-durable-complete
  4. A study to assess the anti-tumor activity and safety of odronextamab in patients with B-cell non-Hodgkin lymphoma that have been previously treated (ELM-2). ClinicalTrials.gov. Updated April 20, 2023. Accessed August 17, 2023. https://classic.clinicaltrials.gov/ct2/show/NCT03888105
  5. Study to investigate the safety and tolerability of odronextamab in patients with CD20+ B-cell malignancies (ELM-1). ClinicalTrials.gov. Updated June 6, 2023. Accessed August 17, 2023. https://classic.clinicaltrials.gov/ct2/show/NCT02290951
Related Videos
Alex Herrera, MD
Grzegorz S. Nowakowski, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Grzegorz S. Nowakowski, MD
T. Jeroen N. Hiltermann, MD, of University of Groningen
Benjamin Besse, MD, PhD, of Institute Gustave Roussy
Jasmin M. Zain, MD
Natasha B. Leighl, MD, BSc, MMSc, of the Princess Margaret Cancer Centre
Grzegorz S. Nowakowski, MD
Yi-Long Wu, MD, PhD, of the Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University